OKYO Pharma director receives 3,500-share option grant

OKYO Pharma director Bernard Denoyer received an option grant for 3,500 shares of OKYO Pharma Ltd common shares.

Accepted by SEC EDGAR 06/10/2026 - 05:00 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

OKYO Pharma director Bernard Denoyer received an option grant for 3,500 shares of OKYO Pharma Ltd common shares. The options have an exercise price of $1.85 per share and are exercisable into 3,500 common shares. After this grant, Denoyer holds options on 35,190 shares in total. The options are scheduled to expire on June 8, 2036, indicating a long-dated, compensation-related award rather than an open-market share purchase or sale.

Insider Trade Summary

Grant/Award: 3,500 shares

Grant/Award 1 txn

Insider Denoyer Bernard

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Option	3,500	$1.85	$6K

Holdings After Transaction: Option — 35,190 contracts (Direct)

Key Figures

Option grant size: 3,500 options Exercise price: $1.85 per share Underlying shares: 3,500 common shares +2 more

5 metrics

Option grant size 3,500 options Granted on June 8, 2026 to director Bernard Denoyer

Exercise price $1.85 per share Exercise price of newly granted options

Underlying shares 3,500 common shares Shares issuable upon exercise of new options

Total options after grant 35,190 options Total derivative securities held following transaction

Option expiration date June 8, 2036 Expiration of granted options

Key Terms

Grant, award, or other acquisition, Option, Common Shares, derivative securities

4 terms

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Option financial

"security_title: Option with underlying common shares"

An option is a financial contract that gives its holder the right, but not the obligation, to buy or sell a stock at a specified price within a set time. Investors use options like a reservation or coupon to lock in a price, protect against losses, or amplify potential gains with a smaller upfront cost than owning the stock outright, making them useful for hedging, income strategies, or speculative bets.

Common Shares financial

"underlying_security_title: Common Shares"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

derivative securities financial

"derivativeTransactionCount for derivative-type records"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did OKYO Pharma (OKYO) report for Bernard Denoyer?

OKYO Pharma reported that director Bernard Denoyer received an option grant for 3,500 shares. These options are a compensation-related award, not a market purchase, and give him the right to buy common shares at a fixed exercise price.

What is the exercise price of Bernard Denoyer’s new OKYO Pharma stock options?

The granted options have an exercise price of $1.85 per share. This means Denoyer can acquire OKYO Pharma common shares at $1.85 each by exercising the options before they expire, regardless of the future market price.

How many OKYO Pharma shares are covered by Bernard Denoyer’s new option grant?

The new option grant covers 3,500 underlying common shares of OKYO Pharma. Each option is exercisable into one common share, giving Denoyer potential future ownership if he chooses to exercise the options before expiration.

What are Bernard Denoyer’s total OKYO Pharma option holdings after this grant?

After this grant, Bernard Denoyer holds options on a total of 35,190 shares. This figure reflects his post-transaction derivative holdings as reported, representing his potential future right to acquire additional OKYO Pharma common shares.

When do Bernard Denoyer’s newly granted OKYO Pharma options expire?

The newly granted options expire on June 8, 2036. Denoyer must exercise the options on or before that date to acquire the underlying OKYO Pharma common shares at the stated exercise price, or the options will lapse.

Is Bernard Denoyer’s OKYO Pharma option grant a market purchase of shares?

No, the filing shows a grant of options, not a market share purchase. This is a compensation-related award that gives Denoyer the right to buy shares later, rather than an immediate open-market acquisition of OKYO Pharma common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Denoyer Bernard

(Last) (First) (Middle)

14-15 CONDUIT ST

(Street)

LONDON W1S 2XJ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
OKYO Pharma Ltd [ OKYO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option	$1.85	06/08/2026	06/08/2026	A		3,500		06/08/2027	06/08/2036	Common Shares	3,500	$1.85	35,190	D

Explanation of Responses:

Remarks:

Options vest 25% per year over four years beginning on the first anniversary of the grant date

	/s/ Bernard Denoyer	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)